AIFM2 (also known as FSP1, ferroptosis suppressor protein 1) functions as a NAD(P)H-dependent oxidoreductase that serves as a key inhibitor of ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation 12. The protein localizes to the plasma membrane through myristoylation and catalyzes the reduction of coenzyme Q10 (ubiquinone) to ubiquinol, which acts as a lipophilic radical-trapping antioxidant that prevents lipid oxidative damage 12. AIFM2 operates in parallel to the glutathione peroxidase 4 (GPX4) pathway to suppress phospholipid peroxidation and ferroptosis, functioning independently of cellular glutathione levels 12. The protein demonstrates particular importance in vivo, where FSP1 knockout mice show increased lipid peroxidation and robust tumor suppression in lung cancer models 3. AIFM2 expression correlates with ferroptosis resistance across cancer cell lines and serves as a prognostic marker for poor survival in lung adenocarcinoma patients 23. Additionally, AIFM2 is regulated by the NRF2 transcription factor in KEAP1-deficient lung cancers, contributing to both ferroptosis and radiation resistance 4. The protein's dual role in suppressing ferroptosis while promoting cancer progression makes it an attractive therapeutic target for cancer treatment.